PubRank

Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients.

PubWeight™: 3.29‹?› | Rank: Top 1%

🔗 View Article (PMID 27232649)

Published in N Engl J Med on May 27, 2016

Authors

Alexander T Cohen1, Robert A Harrington1, Samuel Z Goldhaber1, Russell D Hull1, Brian L Wiens1, Alex Gold1, Adrian F Hernandez1, C Michael Gibson1, APEX Investigators

Author Affiliations

1: From Guy's and St. Thomas' Hospitals, London (A.T.C.); the Department of Medicine, Stanford University, Stanford (R.A.H.), and Portola Pharmaceuticals, South San Francisco (B.L.W., A.G.) - both in California; the Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School (S.Z.G.), and Beth Israel Deaconess Medical Center (C.M.G.) - both in Boston; the Faculty of Medicine, University of Calgary, Calgary, AB, Canada (R.D.H.); and the Division of Cardiology, Duke University and Duke Clinical Research Institute, Durham, NC (A.F.H.).

Associated clinical trials:

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study) (APEX) | NCT01583218

Computerized Decision Support for Prevention of VTE in Hospitalized Medical Patients Across the Continuum of Care (DC-eALERT) (DC-eALERT) | NCT03728166

Prevalence and Characteristics of Pulmonary Embolism on COVID-19 Patients Presenting Respiratory Symptoms (COVID-EP) | NCT04420312

Articles citing this ↘

Betrixaban in Acutely Ill Medical Patients. N Engl J Med (2016) 0.92

Betrixaban in Acutely Ill Medical Patients. N Engl J Med (2016) 0.90

Betrixaban in Acutely Ill Medical Patients. N Engl J Med (2016) 0.88

N-terminal pro-B-type natriuretic peptide and the risk of stroke among patients hospitalized with acute heart failure: an APEX trial substudy. J Thromb Thrombolysis (2017) 0.88

Thromboprophylaxis after hospital discharge in acutely ill medical patients: need for trials in patients who are at high risk of venous thrombosis. J Thorac Dis (2017) 0.75

Betrixaban in Acutely Ill Medical Patients. N Engl J Med (2016) 0.75

Thromboprophylaxis with enoxaparin and direct oral anticoagulants in major orthopedic surgery and acutely ill medical patients: a meta-analysis. Intern Emerg Med (2017) 0.75

Effect of near-universal hospitalization-based prophylaxis on annual number of venous thromboembolism events in the US. Blood (2017) 0.75

Highlights from the Ninth International Symposium of Thrombosis and Anticoagulation (ISTA IX), October 15, 2016, Salvador, Bahia, Brazil. J Thromb Thrombolysis (2017) 0.75

Articles by these authors ⇆

Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients: An APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban). Circulation (2016) 0.77

Comparison of Fatal or Irreversible Events With Extended-Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy. J Am Heart Assoc (2017) 0.75

The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial. Am Heart J (2016) 0.75